3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
8
Neoplasms
4
Thrombosis
3
Pulmonary Embolism
3
Venous Thrombosis
2
Multiple Myeloma
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Upper Extremity Deep Vein Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Ovarian Neoplasms
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Endometrial Neoplasms
1
Catheter-Related Infections
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Magnetic Resonance Spectroscopy
19
Temozolomide
16
Radiotherapy
10
Specimen Handling
7
Blood Specimen Collection
7
Radiation
6
Bevacizumab
5
Nivolumab
4
Cyclophosphamide
4
Biopsy
4
vorasidenib
3
trametinib
3
pembrolizumab
3
olaparib
3
fludarabine
3
dabrafenib
3
Watchful Waiting
3
Surgical Procedures, Operative
3
Magnetic Resonance Imaging
3
Drug Therapy
3
olutasidenib
2
lutetium Lu 177 dotatate
2
fluorodopa F 18
2
fluciclovine F-18
2
entrectinib
2
contrast agent BR1
2
Restraint, Physical
2
Radiosurgery
2
Microdialysis
2
Flucytosine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Glioma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled